- Investing.com
Dalrada Financial Corporation, together with its subsidiaries, provides solutions that directly address climate change, gaps in the health care industry, and technology needs in the United States, Scotland, Spain, and India. It operates through: Genefic, Dalrada Climate Technology, Dalrada Precision Manufacturing, and Dalrada Technologies divisions. The Genefic division provides care and managing disease states through comprehensive prescription management, education, nursing, and total health solutions; offers authorization and prescription management services; processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and detects immune response to the virus; and provides trained nursing and medical assistants for hospitals and home health facilities. The Dalrada Climate Technology division manufactures industrial heat pump, develops advanced solutions for the harvesting and recycling of energy; provides energy service solutions; general contracting services; and offers custom door and hardware retail store. The Dalrada Precision Manufacturing division helps devise unique manufacturing solutions; designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip, and semiconductor industries; and manufactures and sells deep cleaners, parts washers, and degreasers. The Dalrada Technologies division provides digital engineering for cutting-edge software systems and offers a host of robust digital service; and is involved in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain activities. Dalrada Financial Corporation was incorporated in 1982 and is headquartered in Escondido, California.
Metrics to compare | DFCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDFCOPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | 34.0x | 12.6x | |
PEG Ratio | −0.01 | 0.13 | 0.03 | |
Price/Book | −0.3x | 3.3x | 1.4x | |
Price / LTM Sales | 0.2x | 11.9x | 1.3x | |
Upside (Analyst Target) | - | 33.3% | 16.6% | |
Fair Value Upside | Unlock | −10.8% | 5.3% | Unlock |